June 9, 2014
Study finds the newest hybrid cardiac molecular imaging system highly effective for the detection of disease in the arteries of the heart when compared to industry standard
St. Louis, Mo. (Embargoed until 12:30 pm EDT on Monday, June 9) – Ischemic heart disease, a narrowing of the arteries supplying blood to the heart, is a leading cause of death throughout the world. A hybrid molecular imaging technique called positron emission tomography and magnetic resonance (PET/MR) imaging, which tells doctors vital information about cardiac and arterial function, has been found to be an effective molecular imaging tool for detecting coronary artery disease (CAD), say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.
Often patients suspected of having CAD undergo a stress test called myocardial perfusion imaging (MPI) to smoke out areas of arterial ischemia and risk of myocardial infarction, or heart attack. Many undergo a molecular imaging scan called single photon emission computed tomography (SPECT), but in recent years PET/MR has emerged as a potential alternative due to its superiority for imaging the structures of soft tissues and the physiological function of the heart. This study showed that PET/MR is consistently accurate using coronary angiography as the reference standard for detecting CAD.
“By combining two advanced imaging modalities, PET and MR, cardiac PET/MR imaging allows a union of anatomic information with MR and functional information with PET for a comprehensive view of the of the heart,” said principal author Jeffrey M.C. Lau, MD, PhD, from Washington University in St. Louis, Mo. “This allows us to predict or rule out coronary artery disease with more certainty, and in some instances, it allows us to detect disease processes such as areas of hibernating heart muscle that would not have been detected using conventional stress testing methods like SPECT.”
In addition, cardiac perfusion PET/MR can be performed in a shorter timeframe than SPECT and is associated with a lower dose of radiation per procedure, and MR can be used to produce an almost cinematic, multiple-frame sequence of the motion in specific regions of the heart muscle, most notably the left ventricle, which pumps oxygenated blood back into the body through the aorta. PET also provides quantitative data about blood flow in addition to the visual interpretation of disease.
The study involved 10 patients with reversible ischemia as indicated by SPECT-MPI. Scientists administered a radionuclide PET imaging agent called N-13 ammonia plus an MR contrast agent called gadolinium and the pharmaceutical Regadenoson, which imitates the stress of exercise. The researchers optimized the cardiac PET/MR imaging protocol in order to register areas of reduced perfusion of blood using MR with PET data about myocardial blood flow. The results showed that PET/MR imaging was very accurate in diagnostic coronary artery diseases. In this small sample, PET/MR had 100 percent sensitivity, 80 percent specificity and 100 percent negative predictive value. Those numbers compare favorably to SPECT in this study group.
According to 2014 statistics from the American Heart Association, coronary heart disease caused one out of every six fatalities in the U.S. in 2010. An estimated 620,000 Americans suffered a first heart attack and 295,000 had a recurrent episode. Collectively, heart attacks occur about once every 34 seconds. Coronary events cause about 379,559 deaths each year.
This study was conducted in conjunction with Siemens Medical Solutions and funded in part by Astellas Pharma, Inc.
Scientific Paper 242: Jeffrey Lau, Cardiology, Washington University, St. Louis, MO; Richard Laforest, Jie Zheng, Donna Lesniak, Robert Gropler, Pamela Woodard, Radiology, Washington University, St. Louis, MO; Agus Priatna, Siemens Medical Solutions, Malvern, PA, “13N-Ammonia PET/MR myocardial stress perfusion imaging early experience,” SNMMI’s 61th Annual Meeting, June 7–11, 2014, St. Louis, Missouri.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s more than 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.